{
  "id": 20977608,
  "title": "Glaukos CEO Thomas Burns sells $42.6 million in stock",
  "url": "https://urgent.news/2026/11/21/glaukos-ceo-thomas-burns-sells-42-6-million-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-21T00:46:20.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/glaukos-ceo-thomas-burns-sells-426-million-in-stock-93CH-5042964"
  },
  "original_language": "en",
  "account": "Glaukos Corporation's CEO, Thomas William Burns, recently sold 180,000 shares of the company's stock, netting roughly $42.6 million. The transactions occurred on November 18, 2026, and were executed within a set price range of $232.61 to $245.9 per share. Prior to the sales, Burns acquired the same number of shares by exercising stock options priced at $45.71 each, amounting to $8.23 million. These options were also governed by a pre-arranged Rule 10b5-1 trading plan, which was established on August 20, 2026. The company's shares are currently trading at $237.31, near their 52-week high of $255.19, indicating a 138% return over the past year. Despite posting a loss of $2.91 per share in the previous year, analysts are predicting profitability for the current year with earnings expected to reach $0.67 per share. Following the sales, Burns now holds 65,060 shares of Glaukos common stock, including 48,673 restricted stock units that have not yet vested or been delivered. Additionally, Burns indirectly owns shares through several trusts, including the Burns Family Trust, Burns Annuity Trust, Burns Charitable Remainder Trust, Thomas W. Burns Irrevocable Trust, and Janet M. Burns Irrevocable Trust. Glaukos reported strong third-quarter 2026 financial results, with total revenue reaching $211 million, a 58% increase from the previous year. This success can be attributed to the growth of the Epioxa segment, which has turned the company's profitability positive. Several firms have raised their price targets for Glaukos, including BTIG, H.C. Wainwright, Piper Sandler, Needham, and Mizuho. The company has also announced preliminary fiscal year 2027 revenue guidance of approximately $1 billion, surpassing prior consensus estimates of $852.4 million.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}